脱可里达林通过抑制纤维细胞激活来减轻白素诱导的肺纤维化
Jianhan He1, Huihui Yue1, Shufei Zhang2
1Department of Respiratory and Critical Care Medicine, National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jie Fang Ave, Wuhan, 430030, Hubei, China.
Respiratory research
|April 12, 2025
概括
脱水胆固醇 (DHC) 通过抑制纤维细胞激活,显示了肺纤维化 (PF) 的治疗潜力. 这项研究证明了DHC在PF模型中的有效性,提供了一个有前途的新治疗方法.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 肺纤维化 (PF) 是一种致命的肺病,治疗选择有限.
- 来自Corydalis yanhusuo的脱水胆固醇 (DHC) 已显示出各种药理学效应.
- 在PF管理中DHC的作用需要进一步调查.
研究的目的:
- 在PF模型中评估DHC的治疗有效性.
- 阐明DPH在PF中的作用机制.
主要方法:
- 使用了布莱米辛诱导的PF小鼠模型和人类精确切割肺切片 (hPCLS).
- 通过组织病理学,免疫光和纤维化标志物分析评估了抗纤维菌效应.
- 研究了DHC对人类初级肺纤维细胞 (HPF) 和潜在机制的影响.
主要成果:
- DHC在PF小鼠模型和hPCLS中证明了剂量依赖的治疗疗效.
- DHC降低了纤维素,原1和α-SMA的表达.
- DHC通过向内质网膜应激和TGF-β/SMAD通路来抑制纤维细胞向肌纤维细胞的过渡.
结论:
- 通过抑制纤维细胞激活,DHC为PF提供了一个有前途的治疗策略.
- 初步数据表明,DHC在PF的小鼠模型中是安全和有效的.
相关概念视频
Introduction to Fibroblasts
3.0K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
98
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
98
COPD: Management Using Bronchodilators and Corticosteroids
133
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
133
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


